National Research Corporation (NRC), a key player in the healthcare sector, specializes in providing analytics and insights designed to enhance the patient and employee experience. With a market capitalization of $381.43 million, NRC operates in the health information services industry, offering a suite of subscription-based solutions that empower healthcare organizations with actionable data.
Currently trading at $16.74, NRC’s price change is a slight dip of 0.13, or -0.01%. The stock has demonstrated considerable volatility over the past year, with a 52-week range stretching from $10.13 to $26.17. This wide range signals potential opportunities for investors who can navigate the swings in its market price.
The company’s valuation metrics, such as P/E ratio, PEG ratio, and price/book ratio, are not available, which might concern some investors seeking clarity on NRC’s market valuation. However, NRC’s robust EPS of 1.02 and a remarkable return on equity (ROE) of 72.69% stand out as significant positives. Such a high ROE suggests that NRC is highly effective in generating profits from its equity, a crucial indicator of financial health and operational efficiency.
Revenue growth, however, presents a challenge, showing a decline of 5.00%. This negative growth trajectory might raise questions about NRC’s ability to expand its market presence or enhance its service offerings. Nevertheless, the company reports a solid free cash flow of $9,853,750, which could provide a buffer and allow for strategic investments or acquisitions to bolster future growth.
Dividend-seeking investors will find NRC’s dividend yield of 2.86% appealing, supported by a payout ratio of 47.06%. This indicates that the company distributes a reasonable portion of its earnings back to shareholders while retaining enough capital to reinvest in the business.
From a technical standpoint, NRC’s stock price is trading above both its 50-day and 200-day moving averages, at $14.69 and $16.46 respectively, suggesting an upward trend in the short to medium term. The relative strength index (RSI) of 67.04 indicates that the stock is nearing overbought territory, a cautionary signal for potential price corrections. However, the MACD and Signal Line values of 0.59 and 0.71, respectively, suggest a modest bullish momentum.
Despite the lack of analyst ratings and target prices, which could provide guidance, NRC’s innovative solutions, such as the Huey AI engine, position it well within the competitive healthcare analytics landscape. This AI-driven tool enhances healthcare experience management, offering a unique value proposition that could drive future growth.
Founded in 1981 and headquartered in Lincoln, Nebraska, National Research Corporation has established a strong niche in healthcare analytics, focusing on improving patient and employee experiences. Investors who appreciate the potential of high ROE and a steady dividend might find NRC a compelling addition to their portfolios, especially as the company continues to navigate the evolving healthcare landscape.
